AuNP-DG: Deoxyglucose Labeled Gold Nanoparticles as X-Ray Computed Tomography Contrast Agents for Cancer Imaging
SUMMARY
The targeted metabolic imaging enhancement achieved by deoxyglucose-labeled gold nanoparticles (AuNP-DG) offers superior tumor-specific contrast and improved resolution in computed tomography (CT) scans compared to conventional iodine-based agents, facilitating enhanced cancer diagnosis and treatment planning.
The Unmet Need: Current CT contrast agents lack tumor-specific uptake and sustained imaging performance
- Traditional iodine-based CT contrast agents exhibit limitations such as high osmolality, rapid clearance from circulation, and insufficient tumor specificity, which reduce diagnostic accuracy and compromise imaging resolution in cancer detection. Moreover, these agents do not leverage the distinct metabolic
signatures of tumor cells, thereby impeding precise visualization of malignant tissues. - Advancements in nanotechnology and molecular imaging have driven the development of targeted contrast agents that can integrate metabolic targeting with anatomical imaging. The emergence of nanoparticle-based imaging probes aligns with industry trends emphasizing multifunctional, long-circulating agents that offer enhanced contrast, specificity, and potential therapeutic synergy.
The Proposed Solution: Deoxyglucose-labeled gold nanoparticles as a tumor-targeted CT contrast agent exploiting elevated cancer cell glucose uptake
- The faculty inventor developed a method to use gold nanoparticles conjugated with 2-deoxy-d-glucose (2-DG), exploiting the increased glucose metabolism characteristic of cancer cells to achieve selective tumor uptake and enhanced CT contrast. This approach differs from current iodine-based agents by utilizing gold’s higher X-ray attenuation and the metabolic targeting conferred by 2-DG conjugation, resulting in greater contrast enhancement and longer blood retention. Experimental validation using human alveolar epithelial cancer cells (A-549) demonstrated significantly improved intracellular uptake and microCT contrast compared to controls conjugated with 1-DG or unlabeled nanoparticles. The design supports integrated metabolic and anatomical tumor imaging in a single scan and shows promise for applications in cancer diagnosis and radiation therapy planning.
ADVANTAGES
-
Enhanced tumor-specific targeting via glucose metabolism
-
Superior CT contrast due to high X-ray attenuation of gold
-
Prolonged blood retention relative to iodine agents
-
Lower osmolality reducing patient risK
- Combined metabolic and anatomical imaging capability
APPLICATIONS
- Cancer diagnosis with improved tumor delineation
- Radiation therapy planning incorporating metabolic status
- Preoperative tumor characterization for surgical guidance